Patents by Inventor John S. Kovach

John S. Kovach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 10399993
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: September 3, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Francis Johnson
  • Oxabicycloheptane prodrugs
    Patent number: 10364252
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 30, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
    Publication number: 20190167671
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
    Type: Application
    Filed: November 30, 2018
    Publication date: June 6, 2019
    Inventor: John S. Kovach
  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20190111053
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure (I) or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 18, 2019
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20190046525
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 14, 2019
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE
    Publication number: 20180370983
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: June 26, 2018
    Publication date: December 27, 2018
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S. KOVACH, Francis JOHNSON
  • Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
    Patent number: 10149847
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 11, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS
    Publication number: 20180256565
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Application
    Filed: November 17, 2017
    Publication date: September 13, 2018
    Inventors: John S. Kovach, Salvatore Lecca, Manuel Mameli
  • Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
    Patent number: 10071094
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: September 11, 2018
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20180244690
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
    Patent number: 10023587
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: July 17, 2018
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S Kovach, Francis Johnson
  • Oxabicycloheptane prodrugs
    Patent number: 9988394
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 5, 2018
    Assignee: Lixte Biotechnology Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE
    Publication number: 20170369503
    Abstract: This invention provides compounds having the structure which may be used for the treatment of tumors.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventors: John S KOVACH, Francis JOHNSON
  • Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
    Patent number: 9833450
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 5, 2017
    Assignees: LIXTE BIOTECHNOLOGY, INC., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: John S Kovach, Salvatore Lecca, Manuel Mameli
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20170340628
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 30, 2017
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE
    Publication number: 20170259081
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 14, 2017
    Applicant: LIXTE BIOTECHNOLOGY, INC.
    Inventor: John S. Kovach
  • SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT
    Publication number: 20170240558
    Abstract: Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 24, 2017
    Applicant: Lixte Biotechnology, Inc.
    Inventors: John S. KOVACH, Francis JOHNSON, Ramakrishna SAMUDRALA
  • OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170136008
    Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:
    Type: Application
    Filed: June 19, 2015
    Publication date: May 18, 2017
    Applicants: Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human Service
    Inventors: John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
  • Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
    Patent number: 9526915
    Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: December 27, 2016
    Inventor: John S. Kovach
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20160333024
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: May 13, 2016
    Publication date: November 17, 2016
    Applicant: Lixte Biotechnology, Inc.
    Inventors: JOHN S. KOVACH, ROBERT VOLKMANN, ANTHONY MARFAT